Exploring the first Rimonabant analog-opioid peptide hybrid compound, as bivalent ligand for CB1 and opioid receptors

Adriano Mollica, Sveva Pelliccia, Valeria Famiglini, Azzurra Stefanucci, Giorgia Macedonio, Annalisa Chiavaroli, Giustino Orlando, Luigi Brunetti, Claudio Ferrante, Stefano Pieretti, Ettore Novellino, S. Benyhe, Ferenc Zador, A. Erdei, Edina Szucs, Reza Samavati, Szalbolch Dvrorasko, C. Tömböly, Rino Ragno, Alexandros PatsilinakosRomano Silvestri

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Cannabinoid (CB) and opioid systems are both involved in analgesia, food intake, mood and behavior. Due to the co-localization of µ-opioid (MOR) and CB1 receptors in various regions of the central nervous system (CNS) and their ability to form heterodimers, bivalent ligands targeting to both these systems may be good candidates to investigate the existence of possible cross-talking or synergistic effects, also at subeffective doses. In this work, we selected from a small series of new Rimonabant analogs one CB1R reverse agonist to be conjugated to the opioid fragment Tyr-D-Ala-Gly-Phe-NH2. The bivalent compound (9) has been used for in vitro binding assays, for in vivo antinociception models and in vitro hypothalamic perfusion test, to evaluate the neurotransmitters release.

Original languageEnglish
Pages (from-to)444-451
Number of pages8
JournalJournal of Enzyme Inhibition and Medicinal Chemistry
Volume32
Issue number1
DOIs
Publication statusPublished - 2017

Fingerprint

rimonabant
Cannabinoid Receptor CB1
Opioid Peptides
Opioid Receptors
Opioid Analgesics
Ligands
Aptitude
Cannabinoids
Analgesia
Neurotransmitter Agents
Central Nervous System
Perfusion
Eating
In Vitro Techniques

Keywords

  • Bivalent ligand
  • Cannabinoid receptor CB1R
  • Opioids
  • Pain
  • Rimonabant

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Exploring the first Rimonabant analog-opioid peptide hybrid compound, as bivalent ligand for CB1 and opioid receptors. / Mollica, Adriano; Pelliccia, Sveva; Famiglini, Valeria; Stefanucci, Azzurra; Macedonio, Giorgia; Chiavaroli, Annalisa; Orlando, Giustino; Brunetti, Luigi; Ferrante, Claudio; Pieretti, Stefano; Novellino, Ettore; Benyhe, S.; Zador, Ferenc; Erdei, A.; Szucs, Edina; Samavati, Reza; Dvrorasko, Szalbolch; Tömböly, C.; Ragno, Rino; Patsilinakos, Alexandros; Silvestri, Romano.

In: Journal of Enzyme Inhibition and Medicinal Chemistry, Vol. 32, No. 1, 2017, p. 444-451.

Research output: Contribution to journalArticle

Mollica, A, Pelliccia, S, Famiglini, V, Stefanucci, A, Macedonio, G, Chiavaroli, A, Orlando, G, Brunetti, L, Ferrante, C, Pieretti, S, Novellino, E, Benyhe, S, Zador, F, Erdei, A, Szucs, E, Samavati, R, Dvrorasko, S, Tömböly, C, Ragno, R, Patsilinakos, A & Silvestri, R 2017, 'Exploring the first Rimonabant analog-opioid peptide hybrid compound, as bivalent ligand for CB1 and opioid receptors', Journal of Enzyme Inhibition and Medicinal Chemistry, vol. 32, no. 1, pp. 444-451. https://doi.org/10.1080/14756366.2016.1260565
Mollica, Adriano ; Pelliccia, Sveva ; Famiglini, Valeria ; Stefanucci, Azzurra ; Macedonio, Giorgia ; Chiavaroli, Annalisa ; Orlando, Giustino ; Brunetti, Luigi ; Ferrante, Claudio ; Pieretti, Stefano ; Novellino, Ettore ; Benyhe, S. ; Zador, Ferenc ; Erdei, A. ; Szucs, Edina ; Samavati, Reza ; Dvrorasko, Szalbolch ; Tömböly, C. ; Ragno, Rino ; Patsilinakos, Alexandros ; Silvestri, Romano. / Exploring the first Rimonabant analog-opioid peptide hybrid compound, as bivalent ligand for CB1 and opioid receptors. In: Journal of Enzyme Inhibition and Medicinal Chemistry. 2017 ; Vol. 32, No. 1. pp. 444-451.
@article{0deeb40f2edc44eb8d41062f1f81cb66,
title = "Exploring the first Rimonabant analog-opioid peptide hybrid compound, as bivalent ligand for CB1 and opioid receptors",
abstract = "Cannabinoid (CB) and opioid systems are both involved in analgesia, food intake, mood and behavior. Due to the co-localization of µ-opioid (MOR) and CB1 receptors in various regions of the central nervous system (CNS) and their ability to form heterodimers, bivalent ligands targeting to both these systems may be good candidates to investigate the existence of possible cross-talking or synergistic effects, also at subeffective doses. In this work, we selected from a small series of new Rimonabant analogs one CB1R reverse agonist to be conjugated to the opioid fragment Tyr-D-Ala-Gly-Phe-NH2. The bivalent compound (9) has been used for in vitro binding assays, for in vivo antinociception models and in vitro hypothalamic perfusion test, to evaluate the neurotransmitters release.",
keywords = "Bivalent ligand, Cannabinoid receptor CB1R, Opioids, Pain, Rimonabant",
author = "Adriano Mollica and Sveva Pelliccia and Valeria Famiglini and Azzurra Stefanucci and Giorgia Macedonio and Annalisa Chiavaroli and Giustino Orlando and Luigi Brunetti and Claudio Ferrante and Stefano Pieretti and Ettore Novellino and S. Benyhe and Ferenc Zador and A. Erdei and Edina Szucs and Reza Samavati and Szalbolch Dvrorasko and C. T{\"o}mb{\"o}ly and Rino Ragno and Alexandros Patsilinakos and Romano Silvestri",
year = "2017",
doi = "10.1080/14756366.2016.1260565",
language = "English",
volume = "32",
pages = "444--451",
journal = "Journal of Enzyme Inhibition and Medicinal Chemistry",
issn = "1475-6366",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Exploring the first Rimonabant analog-opioid peptide hybrid compound, as bivalent ligand for CB1 and opioid receptors

AU - Mollica, Adriano

AU - Pelliccia, Sveva

AU - Famiglini, Valeria

AU - Stefanucci, Azzurra

AU - Macedonio, Giorgia

AU - Chiavaroli, Annalisa

AU - Orlando, Giustino

AU - Brunetti, Luigi

AU - Ferrante, Claudio

AU - Pieretti, Stefano

AU - Novellino, Ettore

AU - Benyhe, S.

AU - Zador, Ferenc

AU - Erdei, A.

AU - Szucs, Edina

AU - Samavati, Reza

AU - Dvrorasko, Szalbolch

AU - Tömböly, C.

AU - Ragno, Rino

AU - Patsilinakos, Alexandros

AU - Silvestri, Romano

PY - 2017

Y1 - 2017

N2 - Cannabinoid (CB) and opioid systems are both involved in analgesia, food intake, mood and behavior. Due to the co-localization of µ-opioid (MOR) and CB1 receptors in various regions of the central nervous system (CNS) and their ability to form heterodimers, bivalent ligands targeting to both these systems may be good candidates to investigate the existence of possible cross-talking or synergistic effects, also at subeffective doses. In this work, we selected from a small series of new Rimonabant analogs one CB1R reverse agonist to be conjugated to the opioid fragment Tyr-D-Ala-Gly-Phe-NH2. The bivalent compound (9) has been used for in vitro binding assays, for in vivo antinociception models and in vitro hypothalamic perfusion test, to evaluate the neurotransmitters release.

AB - Cannabinoid (CB) and opioid systems are both involved in analgesia, food intake, mood and behavior. Due to the co-localization of µ-opioid (MOR) and CB1 receptors in various regions of the central nervous system (CNS) and their ability to form heterodimers, bivalent ligands targeting to both these systems may be good candidates to investigate the existence of possible cross-talking or synergistic effects, also at subeffective doses. In this work, we selected from a small series of new Rimonabant analogs one CB1R reverse agonist to be conjugated to the opioid fragment Tyr-D-Ala-Gly-Phe-NH2. The bivalent compound (9) has been used for in vitro binding assays, for in vivo antinociception models and in vitro hypothalamic perfusion test, to evaluate the neurotransmitters release.

KW - Bivalent ligand

KW - Cannabinoid receptor CB1R

KW - Opioids

KW - Pain

KW - Rimonabant

UR - http://www.scopus.com/inward/record.url?scp=85015583368&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015583368&partnerID=8YFLogxK

U2 - 10.1080/14756366.2016.1260565

DO - 10.1080/14756366.2016.1260565

M3 - Article

C2 - 28097916

AN - SCOPUS:85015583368

VL - 32

SP - 444

EP - 451

JO - Journal of Enzyme Inhibition and Medicinal Chemistry

JF - Journal of Enzyme Inhibition and Medicinal Chemistry

SN - 1475-6366

IS - 1

ER -